Internal Medicine · Forset Hills, NY
NPI
1861587438
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
9830 67th Avenue, Suite Ff
Forset Hills, NY, 11374
Phone (718) 896-2200
Groups this clinician bills Medicare through
Medicare paid, 2024
$340K
6,103 services
Medicare patients, 2024
250
Average age 77
Drug cost, 2024
$5.3M
23,765 prescriptions
Company payments, 2025
$1,621
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arkady Pinkhas was code 99213 (office e&m - established), 1,668 times for 226 patients. In total Arkady Pinkhas billed 6,103 services in 32 codes, and Medicare paid $340K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,668 | 226 | $79.71 | $133K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,204 | 149 | $53.08 | $64K |
| 96365 Intravenous Infusion, Hydration | Office | 622 | 124 | $58.25 | $36K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 622 | 124 | $0.52 | $322 |
| 99214 Office E&M - Established | Office | 558 | 225 | $109.33 | $61K |
| 36415 Venipuncture Blood Collection | Office | 420 | 193 | $8.65 | $3,631 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 157 | 157 | $146.24 | $23K |
| G0442 Annual alcohol misuse screening, 5 to 15 minutes | Office | 149 | 149 | $21.62 | $3,221 |
| 96372 Injection Administration | Office | 119 | 39 | $12.56 | $1,494 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 117 | 38 | $1.01 | $118 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 76 | 76 | $21.61 | $1,643 |
| 93000 Electrocardiogram | Office | 73 | 60 | $12.57 | $918 |
| J7614 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | Office | 69 | 41 | $0.04 | $2.96 |
| 94640 Treatment - Miscellaneous | Office | 67 | 41 | $7.62 | $511 |
| 94664 E&M - Miscellaneous | Office | 67 | 41 | $17.11 | $1,146 |
By year: 2022 $326K for 5,310 services; 2023 $355K for 6,112 services; 2024 $340K for 6,103 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 420 | 193 | $8.65 | $3,631 |
Medicare prescription drug claims, 2024
In 2024, the drug Arkady Pinkhas prescribed most often to Medicare patients was Diclofenac Sodium, with 839 prescriptions and refills. In total Arkady Pinkhas wrote 23,765 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diclofenac Sodium Generic | 839 | 860 | 104 | $590K |
| Amlodipine Besylate Generic | 747 | 877 | 104 | $1,388 |
| Linzess Linaclotide | 742 | 842 | 91 | $425K |
| Gabapentin Generic | 518 | 634 | 87 | $1,748 |
| Metoprolol Succinate Generic | 510 | 598 | 67 | $3,556 |
| Losartan Potassium Generic | 499 | 539 | 67 | $1,645 |
| Rosuvastatin Calcium Generic | 486 | 580 | 67 | $2,079 |
| Vascepa Icosapent Ethyl | 479 | 490 | 57 | $154K |
| Zenpep Lipase/Protease/Amylase | 455 | 468 | 50 | $527K |
| Atorvastatin Calcium Generic | 454 | 562 | 76 | $1,453 |
| Tamsulosin Hcl Generic | 400 | 454 | 55 | $2,824 |
| Metformin Hcl Generic | 396 | 486 | 49 | $1,188 |
| Sertraline Hcl Generic | 375 | 431 | 59 | $1,053 |
| Myrbetriq Mirabegron | 345 | 353 | 42 | $150K |
| Creon Lipase/Protease/Amylase | 324 | 349 | 46 | $302K |
Brand drugs: 7,523 claims; generic drugs: 15,914 claims; opioid claims: 66.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arkady Pinkhas $1,621 ($1,621 in general payments such as food, travel and fees) from 15 companies. The largest payer was Abbvie Inc. with $402.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 21 | $402 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $241 |
| Aimmune Therapeutics, Inc. | 4 | $215 |
| Ardelyx, Inc. ARDX | 8 | $193 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $111 |
| Amgen Inc. AMGN | 4 | $87.43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 3 | $69.94 |
| Axsome Therapeutics, Inc. AXSM | 2 | $61.29 |
| GlaxoSmithKline, LLC. GSK | 2 | $49.03 |
| Pfizer Inc. PFE | 2 | $45.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.